In-process research and development (IPR&D) represents one of the most conceptually challenging intangible assets to value. It encompasses R&D projects that are actively underway at the acquisition date but not yet complete — drug candidates in clinical trials, software products in beta testing, technology prototypes approaching commercialisation.
Under IFRS 3, IPR&D acquired in a business combination is recognised as a separate intangible asset at fair value, regardless of whether it would have been capitalised under IAS 38 by the original developer. This treatment reflects the economic reality that a buyer pays for the pipeline's potential — and that potential has measurable value.
The significance is enormous. In pharmaceutical and biotech acquisitions, IPR&D can represent 50-80% of the total identifiable intangible asset value. In technology acquisitions, IPR&D projects nearing completion can be the primary deal driver.
IPR&D illustrates the most dramatic recognition asymmetry in intangible asset accounting:
This asymmetry means that a company with an identical R&D pipeline to a competitor may show dramatically different balance sheet values — zero if internally developed, potentially billions if acquired.
IPR&D is recognised at fair value in a business combination regardless of its stage of completion. This is one of the most significant differences between IAS 38 and IFRS 3 — and one that makes acquisition accounting for R&D-intensive businesses particularly complex and consequential.
The standard approach for IPR&D valuation is the risk-adjusted net present value (rNPV) method — a variant of the income approach that explicitly incorporates the probability of successful completion:
Estimate the revenue and profit the completed product or technology would generate if the R&D succeeds. This is the "success case" cash flow projection.
Calculate the cost to complete the R&D — remaining clinical trials, development sprints, testing, regulatory filings, and launch preparations.
Apply stage-appropriate probability of technical and commercial success. In pharmaceuticals, published success rates by clinical phase provide robust benchmarks.
Use a discount rate reflecting the risk profile of the project, which is typically higher than the rate for completed technology due to the development uncertainty.
The pharmaceutical industry provides the most robust probability benchmarks for IPR&D valuation:
| Clinical Phase | Cumulative Success Probability |
|---|---|
| Preclinical to approval | 5-10% |
| Phase I to approval | 10-15% |
| Phase II to approval | 15-25% |
| Phase III to approval | 50-70% |
| Regulatory filing to approval | 85-95% |
These probabilities are applied to the success-case cash flows, ensuring the valuation reflects the genuine uncertainty of the development outcome.
A biotech company is acquired with a Phase II oncology drug candidate. The success-case projection estimates £500 million in cumulative revenue over a 10-year product lifecycle, with £80 million in remaining development costs. Phase II to approval probability: 20%. Risk-adjusted NPV at an 18% discount rate: approximately £28 million. This represents the fair value of the IPR&D — the probability-weighted expected value of the pipeline asset.
Once recognised, IPR&D follows specific accounting rules:
No amortisation during development. IPR&D is not amortised while the project is in progress. It remains on the balance sheet at the acquired fair value (less any impairment).
Annual impairment testing. IPR&D that is not yet available for use must be tested for impairment at least annually, and whenever there is an indication of impairment.
Reclassification on completion. When the R&D project is successfully completed, the IPR&D is reclassified to completed technology and amortised over its estimated useful life.
Write-off on abandonment. If the project fails or is abandoned, the IPR&D is written off immediately — charged as an impairment loss to the income statement. This is one of the most visible P&L impacts of acquisition accounting.
IPR&D write-offs from failed projects can represent billions in losses for acquirers. The pharmaceutical industry has seen numerous cases where acquired IPR&D was written off after clinical trial failures — sometimes exceeding the original acquisition premium. Accurate probability assessment at the time of acquisition is essential; overly optimistic success assumptions lead to overstated IPR&D values and larger subsequent write-offs.
While pharmaceutical R&D receives the most attention, IPR&D is relevant across all R&D-intensive industries:
| Industry | Typical IPR&D Assets | Key Valuation Factors |
|---|---|---|
| Software | Products in development, platform upgrades | Time-to-market, competitive landscape, beta traction |
| Semiconductors | New chip designs, process node development | Fabrication risk, design-win pipeline, yield uncertainty |
| Automotive | ADAS features, EV powertrain development | Regulatory approval timeline, platform adoption |
| Clean energy | New materials, efficiency improvements | Technical feasibility, scale-up risk |
| Medical devices | Devices in regulatory review | Clinical evidence, FDA/CE approval probability |
Acquirers frequently pay a premium for businesses with rich R&D pipelines precisely because the pipeline represents future revenue potential beyond the current product portfolio. Accurate IPR&D valuation is essential for understanding how much of the purchase price is supported by identifiable assets (including IPR&D) versus residual goodwill that may never generate the expected returns.
In-process R&D is one of ten technology-based intangible assets under IFRS 3. For the full taxonomy, see 35 types of intangible assets. For IAS 38 capitalisation rules, read IAS 38 explained.
Tony Hillier is an Advisor at Opagio with over 30 years of experience in structured finance, M&A advisory, and intangible asset valuation. Meet the team.
Estimate the value of your intangible assets using industry-standard methods like Relief from Royalty, MPEEM, and With & Without.
A comprehensive guide to identifying, protecting, and valuing trade secrets as technology-based intangible assets under IFRS 3. Covers legal protection frameworks, the relationship between secrecy and value, and practical valuation approaches.
Read more →
How to value proprietary algorithms and AI/ML models as technology-based intangible assets under IFRS 3. Covers the distinction between the algorithm, the model, and the training data, with practical valuation guidance for AI-first acquisitions.
Read more →
How to value databases and data collections as technology-based intangible assets under IFRS 3. Covers the cost, income, and market approaches to data valuation, with practical guidance on data quality assessment.
Read more →Get the latest insights on intangible asset growth and productivity delivered to your inbox.
Book a free consultation to see how Opagio Intangibles can help your business.